Pasithea Therapeutics Corp is a biotech company aiming to solve one of the world’s biggest clinical problems: brain disorders. The long-term aim is to translate research into clinic-ready drugs. Pasithea’s primary focus is on drug development. The aim of their scientific team is to develop new medications that provide better and longer-lasting results for individuals with mental health issues.
Stock Performance
Pasithea News 4 articles
- Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
- Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
- Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
- Pasithea Therapeutics to Call Special Meeting of Stockholders
